Pfizer, BioNTech's COVID-19 vaccine expected to be ready for approval by year end

The experimental vaccine, which showed promise against the fast-spreading respiratory illness in early stage human testing, is expected to move into a large trial involving 30,000 healthy participants later this month, pending regulatory nod.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news